GlobalData

it went from $3.67 trillion as on 31 December 2023 to $4 trillion as on 31 March 2024

Alzheon has recently presented promising interim results from its Phase II Biomarker Trial (NCT04693520) of its oral,…

MASH drugs secured over $5.7 billion in total partnership deal value from 2018 to 2024YTD, where 2024YTD is already the top year…

It is the first new therapy to gain FDA approval in over 15 years

The pharma industry has experienced a notable uptick in licensing agreements for innovator drugs incorporating clustered regularly…

GlobalData’s survey “Generic Drugs - Physician Perspective” uncovered that if cost was not the primary factor, overall close to 40…

According to GlobalData’s Pharmaceutical Intelligence Center, from 2019 to 2023, 673 deals (strategic alliances) occurred among…

According to GlobalData, there are 11 vaccines in late-stage development* for TB globally

GlobalData’s patient-based forecast reveals that the BRAF inhibitor market for melanoma will reach a key milestone by 2028, with…

Shift could reflect a changing demand away from oncology toward addressing metabolic disorders